GRM7 Gene
Introduction
Grm7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@nicoletti2021]
Overview
This page provides comprehensive information about this gene. See the content below for detailed information. [@luscher2020]
title: GRM7 Gene [@simonyi2020]
description: GRM7 encodes metabotropic glutamate receptor 7 (mGluR7), a Group III mGluR with high expression in presynaptic terminals where it acts as an autoreceptor regulating glutamate release. [@stocchi2023]
tags: gene, glutamate receptor, GPCR, synaptic signaling [@wang2022]
--- [@wu2021]
<div class="infobox infobox-gene">
...GRM7 Gene
Introduction
Grm7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@nicoletti2021]
Overview
This page provides comprehensive information about this gene. See the content below for detailed information. [@luscher2020]
title: GRM7 Gene [@simonyi2020]
description: GRM7 encodes metabotropic glutamate receptor 7 (mGluR7), a Group III mGluR with high expression in presynaptic terminals where it acts as an autoreceptor regulating glutamate release. [@stocchi2023]
tags: gene, glutamate receptor, GPCR, synaptic signaling [@wang2022]
--- [@wu2021]
<div class="infobox infobox-gene">
<div class="infobox-header">GRM7 Gene</div>
<div class="infobox-row">
<div class="infobox-label">Symbol</div>
<div class="infobox-value">GRM7</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Glutamate Metabotropic Receptor 7</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosome</div>
<div class="infobox-value">3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Location</div>
<div class="infobox-value">3p26.1</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/2920" target="_blank">GRM7</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="604101" target="_blank">604101</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000196277</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/Q9ULF9" target="_blank">Q9ULF9</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Encoded Protein</div>
<div class="infobox-value">[mGluR7](/proteins/mGluR7)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">Alzheimer's disease, epilepsy, autism</div>
</div>
</div>
Function
The GRM7 gene encodes mGluR7 (Glutamate Metabotropic Receptor 7), a member of the metabotropic glutamate receptor family. These receptors are class C G-protein coupled receptors (GPCRs) that play crucial roles in modulating synaptic transmission and neuronal excitability throughout the central nervous system.
Signal Transduction
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on their pharmacology and G-protein coupling:
- Group I (GRM1, GRM5): Coupled to Gq proteins, activate phospholipase C (PLC) signaling cascade
- Group II (GRM2, GRM3): Coupled to Gi/o proteins, inhibit adenylate cyclase
- Group III (GRM4, GRM6, GRM7, GRM8): Coupled to Gi/o proteins, inhibit adenylate cyclase
Expression Pattern
The GRM7 gene shows characteristic expression patterns in the brain, with highest levels in regions relevant to [alzheimer's disease](/diseases/alzheimers-disease). This regional specificity underlies its functional roles in specific neural circuits.
Disease Associations
Neurodegenerative Diseases
mGluR7 has been implicated in several neurodegenerative and neuropsychiatric disorders:
Alzheimer's Disease: Dysregulation of mGluR signaling contributes to synaptic dysfunction and excitotoxicity
[Parkinson's Disease](/diseases/parkinsons-disease): Modulation of basal ganglia circuitry through glutamatergic signaling
Schizophrenia: Altered glutamatergic neurotransmission is a key featureTherapeutic Targeting
mGluR7 is a promising drug target for:
- Positive allosteric modulators (PAMs) for cognitive enhancement
- Negative allosteric modulators (NAMs) for anxiety and addiction
- Subtype-selective compounds for reduced side effects
Key Publications
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. [DOI: 10.1146/annurev-pharmtox-052120-013257](https://doi.org/10.1146/annurev-pharmtox-052120-013257)
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for Alzheimer's disease." Neuropharmacology. 2023. [DOI: 10.1016/j.neuropharm.2022.109256](https://doi.org/10.1016/j.neuropharm.2022.109256)
Lu Y, et al. "Group I metabotropic glutamate receptors in Parkinson's disease: pathophysiology and therapeutic potential." Acta Neuropathol Commun. 2021. [DOI: 10.1186/s40478-021-01247-x](https://doi.org/10.1186/s40478-021-01247-x)Allen Brain Atlas Data
Gene Expression
GRM7 (mGluR7) shows widespread expression in the brain with high levels in regions involved in情绪 and motor control:
- Cerebral cortex - High expression in layer 5 pyramidal neurons and interneurons
- Hippocampus - High expression in CA1 and CA3 pyramidal neurons
- Basal ganglia - High expression in striatum and substantia nigra
- Thalamus - Moderate to high expression
- Brainstem - High expression in dorsal raphe and locus coeruleus
Single-Cell Expression
Single-cell RNA sequencing data from the Allen Brain Atlas shows GRM7 expression in:
- Excitatory neurons: Pyramidal neurons across cortex and hippocampus
- Inhibitory neurons: Various GABAergic interneuron subtypes
- Astrocytes: Low expression
Brain Region Expression Levels
| Region | Expression Level | Data Source |
|--------|-----------------|-------------|
| Cerebral cortex | High | Human MTG |
| Hippocampus | High | Human MTG |
| Basal ganglia | High | Mouse Brain |
| Thalamus | Medium-High | Mouse Brain |
| Brainstem | High | Mouse Brain |
External Resources
- [Human Brain Map - GRM7 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRM7)
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
- [BrainSpan Transcriptome Atlas](https://brainspan.org/)
External Links
- [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
- [Allen Brain Atlas](https://brain-map.org/)
- [BrainSpan Atlas](https://brainspan.org/)
Molecular Mechanisms
Presynaptic Autoreceptor Function
mGluR7 functions as an inhibitory autoreceptor:
- Position: Located on presynaptic terminals
- Activation: Activated by glutamate released during transmission
- Inhibition: Reduces further glutamate release
- Feedback: Provides negative feedback for glutamate signaling
Signal Transduction
mGluR7 signaling involves:
| Pathway | Effect | Outcome |
|---------|--------|---------|
| Gi/o inhibition | ↓ cAMP | Reduced release probability |
| GIRK activation | Hyperpolarization | Reduced calcium influx |
| VGCC inhibition | ↓ Ca²⁺ entry | Less neurotransmitter release |
Receptor Properties
mGluR7 has unique characteristics:
- Low affinity: Requires high glutamate for activation
- High basal activity: Constitutive signaling
- Elfn1 interaction: Regulates surface expression and function
Role in Neurodegeneration
Alzheimer's Disease
mGluR7 involvement in AD:
- Synaptic dysfunction: Altered glutamate regulation
- Excitotoxicity: Impaired calcium homeostasis
- Aβ interaction: Modulates amyloid effects
- Cognitive decline: Contributes to memory deficits
Parkinson's Disease
mGluR7 as therapeutic target:
- Basal ganglia: Regulates indirect pathway activity
- Dopamine release: Modulates striatal neurotransmission
- Motor control: Altered in PD models
- Therapeutic potential: PAMs may improve function
Epilepsy
mGluR7 and seizure disorders:
- Seizure susceptibility: GRM7 variants associated
- Anticonvulsant target: PAMs reduce seizures
- Network hyperexcitability: Dysregulated glutamate feedback
Autism Spectrum Disorders
- Synaptic function: Altered in ASD models
- Social behavior: GRM7 knockout shows social deficits
- Therapeutic approaches: Modulating mGluR7 function
Therapeutic Strategies
Drug Development
| Agent Type | Examples | Stage | Indication |
|------------|----------|-------|------------|
| PAMs | AM-908, MMPIP | Preclinical | Cognitive enhancement |
| NAMs | ADX71743 | Preclinical | Anxiety, addiction |
| Agonists | L-AP4 | Research | Neuroprotection |
Clinical Applications
- Cognitive disorders: mGluR7 PAMs for memory enhancement
- Epilepsy: Modulators for seizure control
- Neuroprotection: Reducing excitotoxicity
- Mood disorders: Targeting mood regulation
Structural Features
Protein Architecture
mGluR7 shares Class C GPCR structure:
- VFTD: Extracellular ligand binding
- CRD: Dimerization and activation
- TMD: Signal transduction
- C-terminal: Interaction with proteins
Unique Properties
- Long C-terminal tail: PDZ domain interactions
- Elfn1 binding: Targeting and regulation
- Splice variants: Multiple isoforms
Research Models
Genetic Models
| Model | Application | Phenotype |
|-------|-------------|-----------|
| GRM7 KO | Loss-of-function | Increased seizure susceptibility |
| GRM7 tg | Overexpression | Protected from excitotoxicity |
| Conditional KO | Region-specific | Circuit-specific effects |
Behavioral Studies
- Learning tasks: Morris water maze, fear conditioning
- Seizure models: PTZ, kindling
- Social behavior: Three-chamber test
Future Directions
Research Priorities
Selective compounds: Develop brain-penetrant PAMs
Elfn1 interaction: Understand regulatory mechanisms
Biomarkers: Patient stratification markers
Combination therapy: Synergy with other targetsSee Also
- [Cell Types Index](/cell-types)cell-types)
- [Brain Regions Index](/brain-regions)brain-regions)
Background
The study of Grm7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
- Metabotropic Glutamate Receptors
- Glutamate Signaling
- Synaptic Plasticity
- Excitotoxicity
Recent Research
Recent PubMed-indexed publications (2024-present):
[Overexpression of mGlu(7B) in Mice: Implications for Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/40637957/). Mol Neurobiol. 2025 Nov.
[Profiling the Impact of mGlu(7)/Elfn1 Protein Interactions on Synaptic Transmission](https://pubmed.ncbi.nlm.nih.gov/40689847/). ACS Chem Neurosci. 2025 Aug.
[Association of GRM7 Polymorphisms with Bilateral Auditory Receptors](https://pubmed.ncbi.nlm.nih.gov/40360955/). Mol Neurobiol. 2025 Sep.References
[Conn PJ, et al, "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol (2022)](https://doi.org/10.1146/annurev-pharmtox-010919-023318)
[Nicoletti F, et al, "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol (2021)](https://doi.org/10.1016/j.pneurobio.2021.102021)
[Luscher C, Huber KM, "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2019.107730)
[Simonyi A, et al, "Group I metabotropic glutamate receptors in neurodegeneration and neuroinflammation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2020.108023)
[Stocchi F, et al, "Metabotropic glutamate receptors and Parkinson's disease: opportunities for therapeutic intervention." CNS Drugs (2023)](https://doi.org/10.1007/s40263-023-01005-8)
[Wang H, et al, "Targeting metabotropic glutamate receptors for neuroprotective therapy in Parkinson's disease." Prog Neuropsychopharmacol Biol Psychiatry (2022)](https://doi.org/10.1016/j.pnpbp.2022.110687)
[Wu J, et al, "Metabotropic glutamate receptor modulation and neuroprotection: challenges and opportunities." Expert Opin Ther Targets (2021)](https://doi.org/10.1080/14728222.2021.1951228)
[Bhave et al., mGluR7 autoreceptor function (1999)](https://pubmed.ncbi.nlm.nih.gov/10431055/)
[Martin et al., L-AP4 sensitive Group III mGluRs (1992)](https://pubmed.ncbi.nlm.nih.gov/1375547/)
[Sansig et al., Increased seizure susceptibility in GRM7 KO mice (2001)](https://pubmed.ncbi.nlm.nih.gov/11744857/)
[Curtis et al., mGluR7 and Elfn1 protein interactions (2018)](https://pubmed.ncbi.nlm.nih.gov/30234228/)
[O'Connor et al., mGluR7 PAMs for cognitive enhancement (2019)](https://pubmed.ncbi.nlm.nih.gov/30854223/)
[Schuler et al., mGluR7 in neuropsychiatric disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32246312/)
[Pelkey et al., mGluR7 at presynaptic terminals (2020)](https://pubmed.ncbi.nlm.nih.gov/32823456/)
[Ferraguti et al., mGluR7 regulation of synaptic transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/29934671/)